SITC’s 30th Anniversary Annual Meeting & Associated Programs: TICA Group, LLC will have a booth at this year’s Annual Meeting from November 4 – November 8, 2015. Drs. Lander and Ichim will be available for strategy planning and discussions on how to best address your clinical research needs.
Checkpoint inhibitors, CAR-T Cell therapy and gene therapy have changed the landscape of cancer treatment. Imagine the difference of where we were 5 years ago versus what can be offered now. Imagine where we will be 5 years from now – plan your 5 year strategy accordingly and make sure you have the correct proactive initiatives in place to put you where you want to be.
Clinical trials for immunotherapy are so different from conventional clinical trials that choosing the correct CRO is critical. This will allow you to ensure you get the right patient population stratified, your samples are analyzed in a manner that not only allows you to identify well-chosen endpoints but allows you to learn about what is going on in your patients’ immune systems and that biomarker discovery is enabled. The intellectual property generated by your studies should be captured and be a significant additional asset from your clinical studies.